Leveraging disease progression modeling to aid clinical decision and optimize drug development for Idiopathic Pulmonary Fibrosis (IPF)

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.